Novo Nordisk reports 22% weight loss with amycretin
2 days ago · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the …
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
6 days ago · Novo Nordisk unveiled topline Phase Ib/IIa data Friday for its next-generation obesity treatment amycretin, which elicited up to 22% weight-loss in adults with overweight or obesity.. …
Novo Nordisk's next-gen obesity treatment hits target in early …
6 days ago · LONDON — An experimental weight loss drug from Novo Nordisk helped patients shed a substantial amount of weight in an early-stage trial, the company said Friday, providing …
Novo Nordisk next-gen shot shows 22% weight loss in early results
6 days ago · One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial …
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t …
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Jan 17, 2025 · Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli …
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection …
Novo Nordisk hails ‘remarkable’ weight loss result for dual …
Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and …
Experimental Oral Drug Shows 'Remarkable' Weight Loss, Novo Nordisk …
Sep 23, 2024 · An experimental new pill from Novo Nordisk, called amycretin, could cause substantial weight loss in people with obesity. The once-daily oral medication is in the same …
Novo Nordisk's Wegovy weight loss drug wins UK approval for …
Jul 23, 2024 · The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy drug to reduce the risk of obese adults suffering from serious heart problems or strokes.
- Some results have been removed